Emerge Energy Services LP (EMES) EPS Estimated At $0.31; Aldeyra Therapeutics (ALDX) Shorts Down By 18.43%

February 12, 2018 - By Pete Kolinski

Analysts expect Emerge Energy Services LP (NYSE:EMES) to report $0.31 EPS on February, 26.They anticipate $1.08 EPS change or 140.26% from last quarter’s $-0.77 EPS. EMES’s profit would be $9.61M giving it 5.69 P/E if the $0.31 EPS is correct. After having $0.18 EPS previously, Emerge Energy Services LP’s analysts see 72.22% EPS growth. The stock decreased 1.53% or $0.11 during the last trading session, reaching $7.06. About 649,270 shares traded. Emerge Energy Services LP (NYSE:EMES) has risen 243.72% since February 12, 2017 and is uptrending. It has outperformed by 227.02% the S&P500.

Aldeyra Therapeutics Incorporated (NASDAQ:ALDX) had a decrease of 18.43% in short interest. ALDX’s SI was 360,800 shares in February as released by FINRA. Its down 18.43% from 442,300 shares previously. With 99,000 avg volume, 4 days are for Aldeyra Therapeutics Incorporated (NASDAQ:ALDX)’s short sellers to cover ALDX’s short positions. The SI to Aldeyra Therapeutics Incorporated’s float is 15.09%. The stock increased 0.74% or $0.05 during the last trading session, reaching $6.8. About 112,751 shares traded or 14.59% up from the average. Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) has declined 18.94% since February 12, 2017 and is downtrending. It has underperformed by 35.64% the S&P500.

Since September 19, 2017, it had 1 buying transaction, and 0 sales for $1.45 million activity. 200,000 shares were bought by PERCEPTIVE ADVISORS LLC, worth $1.45M.

Among 6 analysts covering Aldeyra Therapeutics Inc (NASDAQ:ALDX), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aldeyra Therapeutics Inc had 13 analyst reports since August 13, 2015 according to SRatingsIntel. The stock has “Buy” rating by Stifel Nicolaus on Friday, July 1. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, August 9. The rating was maintained by Canaccord Genuity on Wednesday, June 14 with “Buy”. The rating was initiated by Cowen & Co with “Outperform” on Tuesday, September 8. Cowen & Co maintained the shares of ALDX in report on Thursday, September 14 with “Buy” rating. The stock of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) has “Buy” rating given on Monday, September 26 by H.C. Wainwright. The rating was maintained by H.C. Wainwright with “Buy” on Thursday, June 15. The stock has “Buy” rating by Canaccord Genuity on Wednesday, September 13. The company was maintained on Wednesday, August 9 by Cowen & Co. The firm earned “Buy” rating on Thursday, November 9 by Cantor Fitzgerald.

Investors sentiment increased to 3.13 in 2017 Q3. Its up 1.46, from 1.67 in 2017Q2. It increased, as 3 investors sold Aldeyra Therapeutics, Inc. shares while 5 reduced holdings. 11 funds opened positions while 14 raised stakes. 18.26 million shares or 145.50% more from 7.44 million shares in 2017Q2 were reported. Retail Bank Of Mellon Corp has invested 0% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Morgan Stanley accumulated 9,783 shares or 0% of the stock. Adage Prtn Gru Ltd Liability Corp holds 0.01% or 750,000 shares in its portfolio. Perceptive Advisors Limited Liability has invested 0.85% of its portfolio in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Bancorporation Of America Corporation De has 7,500 shares for 0% of their portfolio. Vanguard Group Inc has invested 0% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Sphera Funds Limited accumulated 1.04M shares. Woodstock reported 48,393 shares. Millennium Mngmt Ltd Liability holds 545,085 shares or 0.01% of its portfolio. 683 Capital Llc invested in 835,514 shares. Barclays Pcl stated it has 0% of its portfolio in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Royal Natl Bank Of Canada holds 9 shares or 0% of its portfolio. Geode Management Ltd owns 75,994 shares for 0% of their portfolio. Northern Tru accumulated 17,267 shares. 29,650 were reported by Hightower Advsrs Lc.

Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. The company has market cap of $130.00 million. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. It currently has negative earnings. The firm was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014.

Among 14 analysts covering Emerge Energy Services (NYSE:EMES), 6 have Buy rating, 2 Sell and 6 Hold. Therefore 43% are positive. Emerge Energy Services had 39 analyst reports since July 30, 2015 according to SRatingsIntel. Wunderlich upgraded Emerge Energy Services LP (NYSE:EMES) rating on Thursday, September 29. Wunderlich has “Buy” rating and $15 target. The stock of Emerge Energy Services LP (NYSE:EMES) earned “Hold” rating by Janney Capital on Wednesday, September 6. The firm has “Hold” rating by Cowen & Co given on Wednesday, October 18. The stock of Emerge Energy Services LP (NYSE:EMES) has “Buy” rating given on Thursday, September 7 by Stifel Nicolaus. The rating was downgraded by DA Davidson on Monday, June 13 to “Underperform”. The stock has “Outperform” rating by Cowen & Co on Friday, August 7. The firm has “Hold” rating by FBR Capital given on Wednesday, December 6. The firm has “Buy” rating by Goldman Sachs given on Friday, January 20. Cowen & Co maintained the shares of EMES in report on Thursday, August 10 with “Hold” rating. As per Tuesday, December 26, the company rating was maintained by Piper Jaffray.

Emerge Energy Services LP, through its subsidiary, Superior Silica Sands LLC, operates an energy services firm in the United States. The company has market cap of $218.78 million. It engages in mining, processing, and distributing silica sand, which is a primary input for the hydraulic fracturing of oil and natural gas wells. It currently has negative earnings. The firm serves oilfield services companies, and exploration and production companies that are engaged in hydraulic fracturing.

Investors sentiment decreased to 0.58 in Q3 2017. Its down 0.92, from 1.5 in 2017Q2. It worsened, as 12 investors sold Emerge Energy Services LP shares while 12 reduced holdings. 5 funds opened positions while 9 raised stakes. 6.79 million shares or 18.65% less from 8.35 million shares in 2017Q2 were reported. Credit Suisse Ag holds 0% or 436,725 shares in its portfolio. Us Fincl Bank De reported 0% of its portfolio in Emerge Energy Services LP (NYSE:EMES). 400 were reported by Nelson Van Denburg Campbell Wealth Management Grp Ltd Llc. Bank Of Montreal Can accumulated 246,000 shares. Sg Cap Management Ltd Llc accumulated 0.13% or 150,989 shares. Walleye Trading Limited Liability Company holds 70,466 shares or 0% of its portfolio. Blackrock has 0% invested in Emerge Energy Services LP (NYSE:EMES). Morgan Stanley reported 0% stake. Pinnacle Lc holds 850 shares. Balyasny Asset Mngmt Ltd Company owns 0.05% invested in Emerge Energy Services LP (NYSE:EMES) for 1.67 million shares. Stifel Corp reported 20,463 shares. Moreover, Citadel Ltd has 0% invested in Emerge Energy Services LP (NYSE:EMES). Finemark Retail Bank And reported 16,000 shares stake. 193,418 were reported by Castleark Mgmt Ltd Liability. Pnc Serv Group Inc has invested 0% in Emerge Energy Services LP (NYSE:EMES).

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>